Topic: commercial manufacturing
GlaxoSmithKline plans to close its skincare products plants in Sligo, Ireland, and lay off its 165 workers over the next three years.
CDMO Minakem is in final qualifications to open its new closed-controlled environment high-containment production facility.
GlaxoSmithKline will cut jobs at its Barnard Castle manufacturing site in the U.K., despite having plowed money into expanding it the past two years.
Bristol-Myers Squibb will move about 90 manufacturing jobs from its DeWitt, New York, facility to plants in Massachusetts and New Jersey.
Two European manufacturing plants discarded by Big Pharma have been bought by Asian companies and reopened.
Shire hopes to start commercial production this year at a $1.2 billion plasma plant in Georgia that it got in its buyout of Baxalta.
Disasters, both natural and manmade, wreaked havoc on pharma supply chains this year, and pharma can expect the threats to only get worse.
Six months after Merck & Co.'s manufacturing were crippled by a global cyberattack, the company says it has mostly recovered.
A Bangladeshi company that would like to sell an antibiotic in the U.K. has been stopped before it started.
Congress has called on Merck CEO Ken Frazier to give full accounting on how badly affected its global manufacturing was by the Petya malware attack.